ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) Q1 2026 Earnings
ZBIO·Reported May 13, 2026·Before market open
Diluted EPS came in at $-1.46 (-82.5% YoY), beat the $-1.47 consensus by $0.01.
Diluted EPS
$-1.46beat by $0.01
Consensus: $-1.47
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about ProShares UltraPro Short NASDAQ Biotechnology's Q1 2026 earnings report.
ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) reported Q1 2026 earnings on May 13, 2026 before market open.
ProShares UltraPro Short NASDAQ Biotechnology reported diluted EPS of $-1.46 for Q1 2026.
EPS beat the consensus estimate of $-1.47 by $0.01.
Compared to the same quarter a year prior, diluted EPS declined 82.5% from $-0.80.
You can read the 8-K earnings release (0001104659-26-059700) and the 10-Q periodic report (0001104659-26-059735) directly on SEC EDGAR. The filing index links above go to sec.gov.